SCHEMBL3313258

SCHEMBL3313258

O=c1[nH]cc(I)c2cc(F)c(F)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPYD Q12882 1/20 0.43
PKM P14618 1/20 0.43
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
CYP19A1 P11511 1/20 0.39
TSHR P16473 1/20 0.39
THPO P40225 1/20 0.39
MTOR P42345 1/20 0.39
HTT P42858 1/20 0.39
HBB P68871 1/20 0.39
PMP22 Q01453 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GPR84 Q9NQS5 1/20 0.38
AR P10275 1/20 0.38
AKR1C3 P42330 1/20 0.38
IDO1 P14902 1/20 0.35
PARP1 P09874 4/20 0.34
TDO2 P48775 2/20 0.33
MPO P05164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28803101 0.79 PARP1 (0.46) DPYDPKMALDH1A1LMNAMAPT
SCHEMBL16697905 0.76 GPR84 (0.57) DPYDGPR84IDO1TDO2MPO
SCHEMBL30308213 0.75 GSK3B (0.37) PKMALDH1A1LMNAMAPTCYP19A1
SCHEMBL22094300 0.75 GSK3B (0.37) PKMALDH1A1LMNAMAPTCYP19A1
SCHEMBL26276532 0.72 AR (0.33) ALDH1A1LMNAMAPTCYP19A1TSHR
SCHEMBL2342422 0.72 GPR84 (0.44) ALDH1A1LMNAMAPTCYP19A1TSHR
SCHEMBL25150835 0.71 DPYD (0.36) DPYDPKMALDH1A1LMNAMAPT
SCHEMBL31714168 0.71 DPYD (0.36) DPYDPKMALDH1A1LMNAMAPT
SCHEMBL23796246 0.71 CHEK1 (0.47) DPYDPKMALDH1A1GPR84PARP1
SCHEMBL22322711 0.71 CHEK1 (0.47) DPYDPKMALDH1A1GPR84AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113391-A1 BICYCLIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC. (JP) 2010-05-06 US disclosed
US-20100113391-A1 BICYCLIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC. (JP) 2010-05-06 US disclosed
US-20100113391-A1 BICYCLIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC. (JP) 2010-05-06 US disclosed
EP-2138482-A1 BICYCLIC HETEROCYCLIC COMPOUND Astellas Pharma Inc. (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113391-A1 BICYCLIC HETEROCYCLIC COMPOUND P2RY12, P2RY4, P2RY1 DPYD 334/4885PKM 3298/4885ALDH1A1 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.